Docetaxel-estramustine in high-risk localized prostate cancer: First results of the French Genitourinary Tumor Group phase III trial (GETUG 12).Karim Fizazi, Stéphane Culine, Marjorie Baciuchka et al.|Journal of Clinical Oncology|2011Cited by 9
A phase II prospective study of gemcitabine and platin-based combination as first-line chemotherapy for metastatic Bellini duct carcinoma patients. Results of GETUG studyStéphane Culine, F. Rolland, Stéphane Oudard et al.|Journal of Clinical Oncology|2005Cited by 3
Phase III study of addition of docetaxel (D) to hormonal therapy (HT) versus HT alone in nonmetastatic high-risk prostate cancer (PC) patients (pts): Final results on PSA progression-free survivalStéphane Oudard, Stéphane Culine, I. Latorzeff et al.|Journal of Clinical Oncology|2011Cited by 3
A risk-adapted study of cisplatin and etoposide, with or without ifosfamide, in patients with metastatic seminoma: Results of the GETUG S99 multicenter prospective studyKarim Fizazi, A. Laplanche, Marie‐Stéphanie Aubelle et al.|Journal of Clinical Oncology|2009Cited by 2
Nonmetastatic, high-risk prostate cancer patients with biochemical relapse after local treatment: A prospective, randomized phase III study comparing hormonal therapy ± docetaxel—An analysis of final safety results.Stéphane Oudard, Stéphane Culine, I. Latorzeff et al.|Journal of Clinical Oncology|2010Cited by 1